
Please try another search
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Name | Age | Since | Title |
---|---|---|---|
Mark Pruzanski | 56 | 2018 | Independent Director |
Thomas O. Daniel | 70 | 2019 | Member of Scientific & Clinical Advisory Board |
Vijay Kumar Kuchroo | 69 | - | Member of Scientific & Clinical Advisory Board |
Martha J. Demski | 71 | 2018 | Independent Director |
Charles McDermott | 52 | 2018 | Independent Director |
Bala S. Manian | 79 | 2017 | Independent Director |
Fred Ramsdell | 63 | - | Member of Scientific & Clinical Advisory Board |
Barbara Troupin | 56 | 2022 | Independent Director |
Peter Colabuono | - | 2024 | Director |
Bruce D. Steel | 59 | 2006 | Co-Founder, President, CEO & Director |
Daniel Mark Bradbury | 64 | 2017 | Executive Chairman |
Stephen Connelly | 43 | 2017 | Chief Scientific Officer & Director |
Brian Gordon Feagan | - | 2025 | Member of Scientific & Clinical Advisory Board |
Bruce E. Sands | - | 2025 | Member of Scientific & Clinical Advisory Board |
Francisco J. Quintana | - | 2025 | Member of Scientific & Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review